Ottawa-Shanghai Joint School of Medicine


QIU Lihua


Tel: 13801946776

Research Interests: 妇科肿瘤


Qiu Lihua, MD, professor and doctoral tutor, is now a chief physician and the associate director of Obs. & Gyn. Department, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. Dr. Qiu used to be a visiting scholar at the Providence College, USA and the University of Sydney, Australia.

Dr. Qiu’ is professional at diagnosis and treatment of gynecological oncology, precancerous lesions of cervix, vaginal intraepithelial neoplasia, lesions of vulva and infection of lower genital tract. From 2005 to now, Dr. Qiu works as Editorial Board Member of Chinese Journal of Practical Gynecology and Obstetrics and Journal of International Reproductive Health/Family Planning. At present, Dr. Qiu is a member of Gynecological Oncology Branch of Chinese Medical Association, vice director member of the Youth Committee of Chinese Obstetricians and Gynecologists Association, vice director member of Gynecological Oncology Branch of Shanghai Medical Association, member of Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association.

Dr. Qiu’s research interests focus on gynecological oncology, such as the mechanism of tumor microenvironment regulating metastasis and drug resistance in epithelial ovarian cancer and clinical as well as basic research on the effects of vaginal microorganism and cervical HPV infection on cervical lesions. She hosted 4 projects of National Natural Science Foundation of China and got the support from Clinical Research Innovation and Cultivation Fund of Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Science and Technology Innovation Action Plan and Project of Shanghai Municipal Education Commission – Gaofeng Clinical Medicine Grant Support. Dr. Qiu had a total of more than 70 research papers published, in which more than 20 were published in SCI cited journals and she was as the first author or corresponding author. In addition, she was also authorized one national invention patents.

As regard to the honors and rewards, Dr. Qiu won Second Prize of 2008 National Science and Technology Progress Award, Second Prize of 2009 Shanghai Medical Science and Technology Award, Third Prize of 2009 Shanghai Science and Technology Progress Award, Second Prize of 2010 Ministry of Education, Science and Technology Progress Award and First Prize of 2017 Shanghai Science and Technology Progress Award.


  1. Niu J, Pan S, Wei Y, Hong Z, Gu L, Di W, Qiu L. Epidemiology and analysis of potential risk factors of high-risk human papillomavirus (HPV) in Shanghai China: A cross-sectional one-year study in non-vaccinated women. J Med Virol. 2022 Feb;94(2):761-770. (Correspondence author)

  2. Niu J, Cheng M, Hong Z, Ling J, Di W, Gu L, Qiu L. The effect of 5-Aminolaevulinic Acid Photodynamic Therapy versus CO2 laser in the Treatment of Cervical Low-grade Squamous Intraepithelial Lesions with High-Risk HPV Infection: A non-randomized, controlled pilot study. Photodiagnosis Photodyn Ther. 2021 Dec;36:102548. (Correspondence author)

  3. Wei Y, Wang W, Cheng M, Hong Z, Gu L, Niu J, Di W, Qiu L. Clinical evaluation of a real-time optoelectronic device in cervical cancer screening. Eur J Obstet Gynecol Reprod Biol. 2021 Nov;266:182-186.

  4. Wu A, Li Q, Ling J, Gu L, Hong Z, Di W, Qiu L. Effectiveness of photodynamic therapy in women of reproductive age with cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). Photodiagnosis Photodyn Ther. 2021 Dec;36:102517.

  5. Cang W, Li Q, Gu L, Hong Z, Hu Y, Di W, Qiu L. Clinical Evaluation of DNA Ploidy for the Triage of HPV-Positive Chinese Women During Cervical Cancer Screening. Cancer Prev Res (Phila). 2021 Mar;14(3):355-362. (Correspondence author)

  6. Gu L, Cheng M, Hong Z, Di W, Qiu L. The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. Photodiagnosis Photodyn Ther. 2021 Mar;33:102172. (Correspondence author)

  7. Cang W, Gu L, Hong Z, Wu A, Di W, Qiu L. Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions. Photodiagnosis Photodyn Ther. 2021 Jun;34:102293. (Correspondence author)

  8. Hu Y, Hong Z, Gu L, Xie L, Yang B, Dai H, Chen H, Zhang B, Huang L, Liu Z, Cheng J, Zhang Y, Zhang Y, Lin J, Qiu L, Di W. Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening. Cancer Epidemiol Biomarkers Prev. 2020 Jun;29(6):1246-1252. (Correspondence author)

  9. Chen Y, Hong Z, Wang W, Gu L, Gao H, Qiu L, Di W. Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women. BMC Infect Dis. 2019 Aug 1;19(1):677. (Correspondence author)

  10. Hu Y, Wu AY, Xu C, Song KQ, Wang WJ, Yin X, Di W, Hong ZB, Qiu LH. MicroRNA-449a Inhibits Tumor Metastasis through AKT/ERK1/2 Inactivation by Targeting Steroid Receptor Coactivator (SRC) in Endometrial Cancer. J Cancer. 2019 Jan 1;10(2):547-555. (Correspondence author)

  11. Shi Q, Xu L, Yang R, Meng Y, Qiu L. Ki-67 and P16 proteins in cervical cancer and precancerous lesions of young women and the diagnostic value for cervical cancer and precancerous lesions. Oncol Lett. 2019 Aug;18(2):1351-1355. (Correspondence author)

  12. Lv Y, Cang W, Li Q, Liao X, Zhan M, Deng H, Li S, Jin W, Pang Z, Qiu X, Zhao K, Chen G, Qiu L, Huang L. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis. 2019 Nov 26;8(12):70. (Correspondence author)

  13. Gu L, Hong Z, Gao H, Qiu L, Di W. Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype. Cytopathology. 2019 Jul;30(4):419-425. (Correspondence author)

  14. Wu AY, Gu LY, Cang W, Cheng MX, Wang WJ, Di W, Huang L, Qiu LH. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation. J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. (Correspondence author)

  15. Wu AY, Hu Y, Cang W, Li D, Wang WJ, Tian Q, Gu LY, Zhang N, Ji F, Qiu LH. Suppressive effect of microRNA-449a on the NDRG1/PTEN/AKT axis regulates endometrial cancer growth and metastasis. Exp Cell Res. 2019 Sep 15;382(2):111468. (Correspondence author)

  16. Hu Y, Li D, Wu A, Qiu X, Di W, Huang L, Qiu L. TWEAK-stimulated macrophages inhibit metastasis of epithelial ovariancancer via exosomal shuttling of microRNA. Cancer Letters, 2017, 393:60-67 (Correspondence author)

  17. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. Gynecol oncol, 2015, 139(2): 355-62  (Correspondence author)

  18. Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W, Qiu L. MicroRNA-7 Inhibits Tumor Metastasis and Reverses Epithelial-Mesenchymal Transition through AKT/ERK1/2 Inactivation by Targeting EGFR in Epithelial Ovarian Cancer. PLoS One, 2014, 9(5): e96718  (Correspondence author)

  19. Wang YF, Liu PF, Duan YR, Yin X, Wang Q, Liu XF, Wang XR, Zhou JH, Wang WW, Qiu LH, Di W. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials, 2014, 35(3): 983-92. (Correspondence author)

  20. Gu L, Dai L, Cao C, Zhu J, Ding C, Xu HB, Qiu L, Di W. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention. PLoS One,2013, 8(3): e57436 (Correspondence author)

  21. Dai L, Gu L, Ding C, Qiu L, Di W. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett. 2009, 283(2): 159~167. Epub 2009 Apr 22 (Correspondence author)

  22. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Wanebo H, Kouttab N, Chu W, Wan Y. Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep. 2006 Oct;16(4):907-13.

  23. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Kouttab N, Chu W, Wan Y. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int J Oncol. 2006 Oct;29(4):1003-11

  24. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B, Wan Y. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol. 2005 Nov; 27(5): 1441-48

  25. Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B, Wan Y. Transient activation of EGFR/AKT cell survival pathway and expression of surviving contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol, 2005 Sep; 27(3): 823-30